DP1 (CPC1): State-backed pharma with cheap multiples but forensic and liquidity concerns
Intrinsic value VND 30,618 vs market VND 30,200 — implied upside 1.4% (confidence: very_low).
Tổng quan doanh nghiệp
Công ty Cổ phần Dược phẩm Trung ương CPC1 (DP1) is a UPCOM-listed pharmaceutical company operating in the Vietnamese dược phẩm sector. Its core activities are drug production and distribution within Vietnam; the company sits in the 'Dược phẩm' ICB3 industry and is majority-owned (65.41%) by Tổng Công ty Dược Việt Nam, a state-owned enterprise.
DP1 is a small, low-liquidity UPCOM stock (avg volume 2w: 2,591 shares) with zero foreign room (0.0%), which constrains institutional inflows. Financial scale in recent years: revenue ranged from VND 2,025.7 bn in 2024 to VND 2,134.4 bn in 2025, with net profit around VND 113.1 bn in 2025. The balance sheet grew: total assets rose to VND 1,928.0 bn in 2025, supporting a reported ROE of 20.5% and ROA of 6.8% in the latest period.
Luận điểm đầu tư
DP1 presents an attractive headline valuation on traditional multiples: P/E of 5.6x, P/B of 1.1x and EV/EBITDA of 9.9x, while EPS is VND 5,390 and BVPS is VND 28,108 per share. These multiples reflect a company generating positive margins (net margin 5.3%, gross margin 13.5%) and a ROE of 20.5%, which can look compelling versus larger, higher-rated peers.
However, several execution and quality issues materially weaken the investment case. Forensics and earnings-quality flags are prominent: Beneish M-Score is -1.6724 (above the -1.78 manipulation threshold) and the reported Earnings Quality score is very low at 26.2/100, with zero cash-conversion and revenue-quality sub-scores. Balance-sheet leverage is elevated (Debt/Equity 2.27) and the model-implied net debt is about VND 559 bn, increasing sensitivity to operational shocks.
Valuation via our blended FCF/PE model yields an intrinsic value of VND 30,618 (blend: 70% DCF, 30% PE), implying only 1.4% upside to the current price. The modelling process flags low confidence (very_low) and liquidity/earnings-quality sanity flags. Given the narrow upside, concentrated SOE ownership (65.4%), illiquidity (avg volume 2w: 2,591) and forensic concerns, the risk-adjusted return profile is unattractive unless transparency and cash-conversion improve materially.
Diễn giải định giá
Blended intrinsic valuation combining a 10-year DCF (70% weight) and a PE-based valuation (30% weight).
- Base FCF used: VND 32,761,429,590 (input base_fcf).
- WACC of 10.0% and terminal growth of 4.0% drive the DCF; TV contributes 59.73% of enterprise value.
- PE leg uses a fair PE of 8.06 and a PE cap of 25.
- Model blend weights: DCF 0.7, PE 0.3; calibrated (isotonic) intrinsic value VND 30,618 from a raw intrinsic VND 20,275.1.
The blended intrinsic value implies only a 1.4% upside versus the market price; model confidence is very_low. The valuation is sensitive to WACC, terminal growth and cash conversion assumptions (TV accounts for ~59.7% of value), and the model carries sanity flags for illiquidity and low earnings quality — we have low confidence that the calibrated value fully reflects execution and reporting risk.
Các luận điểm cần cân nhắc
- Cheap headline multiples: P/E 5.6x and P/B 1.1x with EPS VND 5,390 and BVPS VND 28,108 suggest room for rerating if earnings quality and cash conversion improve.
- High reported ROE of 20.5% indicates strong reported profitability relative to equity base.
- Majority SOE ownership (65.41%) provides potential operational stability, preferential access to state distribution channels and less likelihood of hostile shareholder dilution.
- Forensic and quality flags: Beneish M-Score -1.6724 (above the -1.78 threshold) and low Earnings Quality 26.2/100 — risk of aggressive accounting and profit non-sustainability.
- Low liquidity (avg volume 2w: 2,591) and zero foreign room (0.0%) constrain rerating catalysts and amplify price volatility on weak flows.
- High leverage (Debt/Equity 2.27) and model net debt ~VND 559 bn increase vulnerability to margin compression or working-capital stress.
- Model calibration and sanity flags (illiquid, low_earnings_quality, manipulation_risk) produce very_low confidence in the intrinsic value (VND 30,618), limiting conviction.
Bối cảnh ngành
The Vietnamese pharmaceutical sector is a mix of SOE-backed distributors, private manufacturers and small-cap specialty producers. Sector dynamics include pressure from generic substitution, pricing oversight and public procurement rules that can compress margins. VAS accounting and state-related transactions can create differences in reported profit recognition versus international peers, increasing the need for forensic review.
Regulatory and market context matters: state ownership often brings operational support (procurement channels, preferential contracts) but also mandates around dividends and possible capital allocation limits. For UPCOM-listed small caps, foreign ownership limits and low liquidity are common — DP1's foreign_room is 0.0% and two-week average volume is low, which reduces the pool of potential buyers and can mute rerating even if fundamentals improve. Peer median implied upside in our coverage is 12.1%, whereas DP1's implied upside is only 1.4% with very_low model confidence.
Yếu tố rủi ro
- Earnings manipulation risk: Beneish M-Score -1.6724 exceeds the -1.78 threshold and red-flag notes indicate a year-over-year M-Score increase of 0.66.
- Very poor earnings quality (26.2/100) with cash-conversion and revenue-quality sub-scores at zero — reported net profit may not convert to cash.
- Liquidity constraints: avg volume 2w of 2,591 and UPCOM listing reduce ability to exit positions without price impact.
- High leverage: Debt/Equity 2.27 and model net debt roughly VND 559 bn raise refinancing and interest-rate sensitivity.
- Concentrated ownership: 65.41% held by Tổng Công ty Dược Việt Nam limits free-float and may delay governance improvements or minority-friendly actions.
- Model and valuation risk: intrinsic value calibration moved from raw VND 20,275.1 to VND 30,618 with isotonic adjustment and carries 'very_low' confidence and sanity flags.
- No dividend yield (0.0%) limits cash-return while investors wait for capital appreciation.
Yếu tố có thể tác động
- Improvement in cash-conversion metrics or audited disclosures that raise Earnings Quality from current 26.2/100.
- A corporate governance event (partial sell-down or listing upgrade) that increases free-float and foreign room.
- Stronger procurement contracts or formulary wins linked to state distributor network that lift top-line growth above the current CAGR.
- Debt reduction or refinancing that meaningfully lowers Debt/Equity from 2.27 and reduces leverage risk.
Đánh giá dấu hiệu kế toán
Forensic flags are the dominant concern. The Beneish M-Score (-1.6724) is above the usual manipulation threshold (-1.78) and sits in a moderately elevated risk band; the report notes an increase year-over-year, which raises the probability of aggressive accounting. Earnings Quality at 26.2/100 — with explicit zero scores on cash conversion and revenue quality — suggests reported profits have weak cash backing. Altman Z-Score at 2.15 places the company in a 'grey zone' for distress risk. The concentrated 65.41% SOE ownership is a stabilising factor but does not offset the documented reporting and cash-conversion weaknesses. Overall forensic assessment: moderate manipulation/quality risk, and that is the principal investment concern.
Lịch sử định giá
Model track record spans 9 years (2018–2026) with a hit rate of 62.5% — modestly above random but not definitive. Historical average upside for model calls is large (avg_upside_pct 218.2%), reflecting occasional big winners; however, the hit rate indicates that directional calls are correct roughly 5/8 times, so individual-company outcomes remain highly uncertain. Given DP1's very_low model confidence and forensic red flags, past model success provides limited comfort for this specific issuer.
Nội dung do mô hình ngôn ngữ tạo ngày 2026-08-10 từ kết quả mô hình và báo cáo tài chính trên trang này; số liệu có thể phản ánh thời điểm đó. Đây là phân tích mô tả, không cấu thành khuyến nghị mua, bán hoặc nắm giữ.